Updated on 1 July 2014
New treatments to counter heart diseases have emerged every decade, starting with diagnostic coronary angiography in 1958, by pass surgery in 1969, reintroduction of angioplasty in 1979 and general use of bare metal stents in 1994. Drug eluting stents followed in 2002. "We are working to develop Generx microvascular gene therapy as the next big transformative innovation for the fields of gene therapy and interventional cardiology," Dr Reinhard added.
Generx is designed to stimulate the body's natural healing response to ischemic coronary artery disease by promoting microvascular angiogenesis and arteriogenesis. These together enhance cardiac perfusion( blood flow). The product is likely to be submitted for regulatory approval in the US, Russia, Commonwealth of Independent states and other parts of the world in the near future. Cardium's contract manufacturing partner SAFC based in Carlsbad, California is expected to start commercial manufacture of Generx soon.